NYSE:DPLO - Diplomat Pharmacy Stock Price, Price Target & More

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

Diplomat Pharmacy Inc (NYSE:DPLO) released its quarterly earnings data on Monday, May, 7th. The company reported $0.20 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.21 by $0.01. The company had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.28 billion. Diplomat Pharmacy had a net margin of 0.23% and a return on equity of 8.80%. The company's revenue for the quarter was up 24.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.19 EPS. View Diplomat Pharmacy's Earnings History.

Diplomat Pharmacy is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Diplomat Pharmacy.

Diplomat Pharmacy updated its FY18 earnings guidance on Monday, May, 7th. The company provided EPS guidance of $0.87-$0.97 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.92. The company issued revenue guidance of $5.5-$5.9 billion, compared to the consensus revenue estimate of $5.44 billion.

11 brokers have issued twelve-month price targets for Diplomat Pharmacy's shares. Their forecasts range from $18.00 to $35.00. On average, they expect Diplomat Pharmacy's stock price to reach $26.90 in the next year. This suggests a possible upside of 20.5% from the stock's current price. View Analyst Ratings for Diplomat Pharmacy.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Diplomat Pharmacy include Rite Aid (RAD), Petmed Express (PETS), Taxus Pharmaceuticals (TXSP), HealthWarehouse.com (HEWA) and Dougherty's Pharmacy (MYDP).

News stories about DPLO stock have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Diplomat Pharmacy earned a coverage optimism score of 0.18 on Accern's scale. They also assigned news articles about the company an impact score of 45.10 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Diplomat Pharmacy's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Fred Alger Management Inc. (0.86%), Columbia Partners L L C Investment Management (0.10%), FCG Advisors LLC (0.05%), Municipal Employees Retirement System of Michigan (0.02%), Campbell & CO Investment Adviser LLC (0.01%) and Amalgamated Bank (0.01%). Company insiders that own Diplomat Pharmacy stock include Atheer A Kaddis, Atul Kavthekar, Jeffrey G Park, Joel Saban, Philip R Hagerman and Shawn Tomasello. View Institutional Ownership Trends for Diplomat Pharmacy.

DPLO stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Municipal Employees Retirement System of Michigan and Bank of Montreal Can. Company insiders that have sold Diplomat Pharmacy company stock in the last year include Jeffrey G Park, Philip R Hagerman and Shawn Tomasello. View Insider Buying and Selling for Diplomat Pharmacy.

DPLO stock was purchased by a variety of institutional investors in the last quarter, including FCG Advisors LLC, Columbia Partners L L C Investment Management, Campbell & CO Investment Adviser LLC, Amalgamated Bank, Fox Run Management L.L.C. and Xact Kapitalforvaltning AB. Company insiders that have bought Diplomat Pharmacy stock in the last two years include Atul Kavthekar, Jeffrey G Park and Joel Saban. View Insider Buying and Selling for Diplomat Pharmacy.

Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of DPLO stock can currently be purchased for approximately $22.33.

Diplomat Pharmacy has a market capitalization of $1.85 billion and generates $4.49 billion in revenue each year. The company earns $15.51 million in net income (profit) each year or $0.84 on an earnings per share basis. Diplomat Pharmacy employs 2,419 workers across the globe.

Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]